Evolutionary Tree Capital Management’s Krystal Biotech KRYS Stock Holding History

Evolutionary Tree Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.09M	Sell	8,301 -4,013	-33%	-$1.2M	5.82%	4
2026 Q1	$3.18M	Sell	12,314 -4,497	-27%	-$1.2M	5.98%	3
2025 Q4	$4.14M	Buy	16,811 +4,350	+35%	+$916K	4.81%	5
2025 Q3	$2.2M	Buy	12,461 +165	+1%	+$24.7K	2.4%	21
2025 Q2	$1.69M	Sell	12,296 -1,047	-8%	-$154K	1.79%	24
2025 Q1	$2.41M	Buy	13,343 +2,643	+25%	+$445K	2.8%	16
2024 Q4	$1.68M	Buy	10,700 +1,588	+17%	+$282K	1.71%	25
2024 Q3	$1.66M	Buy	9,112 +177	+2%	+$34.1K	1.66%	24
2024 Q2	$1.64M	Sell	8,935 -161	-2%	-$27K	1.69%	25
2024 Q1	$1.62M	Sell	9,096 -1,476	-14%	-$205K	1.63%	27
2023 Q4	$1.31M	Buy	+10,572	New	+$1.17M	1.45%	29

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Evolutionary Tree Capital Management's KRYS Position: Q2 2026 in Review

Evolutionary Tree Capital Management reduced its Krystal Biotech (KRYS) stake by 33% in Q2 2026, selling an estimated $1.2M and leaving 8,301 shares worth $3.09M. The position accounts for 5.82% of the portfolio, ranked #4.

Evolutionary Tree Capital Management first reported a position in KRYS in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.14M in Q4 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Evolutionary Tree Capital Management held 8,301 shares of Krystal Biotech worth $3.09M as of Q2 2026.
Evolutionary Tree Capital Management sold 4,013 Krystal Biotech shares in Q2 2026, an estimated $1.2M.
Krystal Biotech made up 5.82% of Evolutionary Tree Capital Management's portfolio in Q2 2026, its #4 holding.
Evolutionary Tree Capital Management first reported a position in Krystal Biotech in Q4 2023 and has held it in 11 quarters since.
Evolutionary Tree Capital Management's Krystal Biotech position peaked at $4.14M in Q4 2025.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Evolutionary Tree Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.